Inovio Pharmaceuticals Inc
GBM
Company Profile
Business description
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Contact
660 West Germantown Pike
Suite 110
Plymouth MeetingPA19462
USAT: +1 267 440-4200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
134
Stocks News & Analysis
stocks
ASX listed gold miner under pressure due to lower production
Shares have dropped nearly 20% since lowering 2026 volume guidance.
stocks
3 ASX opportunities after earnings season
Uncovering key opportunities following February’s results.
stocks
Oracle earnings: Solid execution secures revenue target and mitigates investor concerns
We raise our fair value estimate for Oracle stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,819.40 | 9.30 | -0.11% |
| CAC 40 | 8,003.62 | 67.65 | 0.85% |
| DAX 40 | 23,770.39 | 206.38 | 0.88% |
| Dow JONES (US) | 47,160.98 | 214.57 | 0.46% |
| FTSE 100 | 10,416.45 | 98.76 | 0.96% |
| HKSE | 25,868.54 | 34.52 | 0.13% |
| NASDAQ | 22,489.51 | 115.33 | 0.52% |
| Nikkei 225 | 53,700.39 | 50.76 | -0.09% |
| NZX 50 Index | 13,182.23 | 17.65 | 0.13% |
| S&P 500 | 6,733.13 | 33.75 | 0.50% |
| S&P/ASX 200 | 8,614.30 | 4.40 | -0.05% |
| SSE Composite Index | 4,049.91 | 34.88 | -0.85% |